Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8804124 | Seminars in Spine Surgery | 2018 | 5 Pages |
Abstract
Osteopenia and osteoporosis have become increasingly common in the elderly population, as has the concern from treating spinal surgeons. Many adverse surgical outcomes have been associated with poor bone quality, including decreased fusion rates, hardware complications, and osteoporotic fractures. Teriparatide, a recombinant form of parathyroid hormone, has been used as a major pharmaceutical intervention in osteoporosis treatment. This article provides an overview of the mechanism of teriparatide followed by a detailed review of the literature concerning outcomes of medical management with teriparatide in both animal models and humans with osteoporosis/osteopenia. Improved fusion rates and duration, as well as reduced osteoporosis-related complications are evident upon reviewing clinical and radiographic outcomes of teriparatide therapy in spinal surgery patients.
Related Topics
Health Sciences
Medicine and Dentistry
Orthopedics, Sports Medicine and Rehabilitation
Authors
Muhammad Shakib BScN, MSc(c), Hussein Ali BSc, Rakesh MD, Ilyas S. MD, MSc, FRCSC,